Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NYINGI KEMMER

Allopathic & Osteopathic Physicians Internal Medicine Transplant Hepatology

NPI
1962468900
CMS profile
390532
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,638.75

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,638.75 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $2,518.75 1
Mallinckrodt Hospital Products Inc. $2,120.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NYINGI KEMMER

NPI 1962468900 · CMS profile ID 390532

Allopathic & Osteopathic Physicians / Internal Medicine / Transplant Hepatology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962468900?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NYINGI KEMMER, NPI 1962468900, CMS profile ID 390532. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962468900?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NYINGI KEMMER, NPI 1962468900, CMS profile ID 390532. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962468900?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NYINGI KEMMER, NPI 1962468900, CMS profile ID 390532, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962468900?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $4,638.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mallinckrodt Hospital Products Inc. $2,120.0010/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145091724 CMS
Novo Nordisk Inc $2,518.7504/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096839188 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.95 5
PY2023 $2,701.46 10
PY2024 $4,638.75 2
PY2025 $2,747.50 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $10,022.78 8
PY2024 Principal investigator $3,914.00 3
PY2023 Principal investigator $35,375.64 10
PY2022 Principal investigator $12,153.88 6
PY2021 Principal investigator $37,852.91 25
PY2020 Principal investigator $90,666.16 44
PY2019 Principal investigator $225,569.97 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $17,303.68 12/31/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670012755
Principal investigator 1 Allergan Inc. $42,099.25 12/17/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670012745
Principal investigator 1 Allergan Inc. $935.75 12/16/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012741
Principal investigator 1 Intercept Pharmaceuticals, Inc. $8,000.00 12/11/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062393
Principal investigator 1 Allergan Inc. $1,135.00 12/03/2019 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670105573
Principal investigator 1 Intercept Pharmaceuticals, Inc. $10,270.00 12/03/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062387
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,600.00 12/02/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND COMPENSATED LIVER CIRRHOSIS No dispute reported 06/30/2026 639758579
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 11/30/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218153
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 11/30/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218155
Principal investigator 1 Mallinckrodt Enterprises LLC $2,390.48 11/30/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218157
Principal investigator 1 Allergan Inc. $935.75 11/21/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012736
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,068.40 10/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062381
Principal investigator 1 Allergan Inc. $935.75 10/16/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012729
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,978.40 10/10/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062377
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,700.00 10/07/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 639758581
Principal investigator 1 Mallinckrodt Enterprises LLC $1,000.00 09/30/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218151
Principal investigator 1 Allergan Inc. $5,296.25 09/19/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670077289
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 09/15/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218147
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 09/15/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218149
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,134.00 09/12/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062371
Principal investigator 1 Allergan Inc. $6,363.10 08/22/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670067843
Principal investigator 1 Allergan Inc. $935.75 08/06/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670063551
Principal investigator 1 Mallinckrodt Enterprises LLC $100.00 07/31/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218145
Principal investigator 1 Intercept Pharmaceuticals, Inc. $16,126.50 07/25/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062369
Principal investigator 1 PFIZER INC. $3,500.00 07/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING PARALLEL GROUP STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF05221304 ADMINISTERED DAILY FOR 16WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671641607
Principal investigator 1 PFIZER INC. $5,050.00 07/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING PARALLEL GROUP STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF05221304 ADMINISTERED DAILY FOR 16WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671641647
Principal investigator 1 PFIZER INC. $1,690.97 07/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING PARALLEL GROUP STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF05221304 ADMINISTERED DAILY FOR 16WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671641649
Principal investigator 1 PFIZER INC. $2,953.97 07/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING PARALLEL GROUP STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF05221304 ADMINISTERED DAILY FOR 16WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671641651
Principal investigator 1 PFIZER INC. $1,000.00 07/24/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING PARALLEL GROUP STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF05221304 ADMINISTERED DAILY FOR 16WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671641691
Principal investigator 1 Allergan Inc. $7,267.50 07/09/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670055489
Principal investigator 1 Intercept Pharmaceuticals, Inc. $11,186.50 06/18/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062365
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 05/31/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218143
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,827.50 05/23/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
1009742 No dispute reported 06/30/2026 702062363
Principal investigator 1 Allergan Inc. $935.75 05/16/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670046037
Principal investigator 1 Allergan Inc. $20.00 05/09/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670044111
Principal investigator 1 Allergan Inc. $2,422.50 05/07/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670043645
Principal investigator 1 Allergan Inc. $20.00 05/02/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670042837
Principal investigator 1 Mallinckrodt Enterprises LLC $100.00 04/26/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218141
Principal investigator 1 Allergan Inc. $3,500.00 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041413
Principal investigator 1 Allergan Inc. $20.00 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041509
Principal investigator 1 Allergan Inc. $47.50 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041529
Principal investigator 1 Allergan Inc. $20.00 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041543
Principal investigator 1 Allergan Inc. $20.00 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041547
Principal investigator 1 Allergan Inc. $323.76 04/25/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670041587
Principal investigator 1 Allergan Inc. $2,565.00 04/23/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670039389
Principal investigator 1 Allergan Inc. $323.76 04/23/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040119
Principal investigator 1 Allergan Inc. $20.00 04/18/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038307
Principal investigator 1 Allergan Inc. $430.00 04/18/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038311
Principal investigator 1 Allergan Inc. $20.00 04/18/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038379
Principal investigator 1 Allergan Inc. $783.75 03/28/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670035069
Principal investigator 1 Allergan Inc. $20.00 03/12/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670030303
Principal investigator 1 Allergan Inc. $5,460.60 02/26/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670026909
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 02/25/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218139
Principal investigator 1 Allergan Inc. $935.75 02/12/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670024021
Principal investigator 1 Allergan Inc. $5,555.60 01/29/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670019849
Principal investigator 1 Allergan Inc. $5,000.00 01/29/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670020145
Principal investigator 1 Allergan Inc. $20.00 01/29/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670020623
Principal investigator 1 Allergan Inc. $1,871.50 01/15/2019 Non-covered Recipient Entity
FLORIDA HEALTH SCIENCES CENTER INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670016593
Principal investigator 1 Mallinckrodt Enterprises LLC $50.00 01/04/2019 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1 No dispute reported 06/30/2026 703218137